Lung cancer immunotherapy is ineffective and requires timely adjustment of the treatment program under doctor’s guidance. Immunotherapy can achieve good therapeutic effect by improving the patient’s immune system, activating stronger anti-tumor immune response, or improving the recognition ability of the immune system to cancer cells. Lung cancer immunotherapy should be changed as soon as possible if it has no effect, such as undergoing radiotherapy treatment and then re-using immunotherapy, and some patients will benefit. A full set of genetic test can also be performed to find effective targets for targeted therapy. In addition, immunotherapy can be combined with anti-angiogenic drugs, such as immunotherapy combined with bevacizumab. In addition, it is also possible to switch to a different immune drug or dual-immunity combination therapy, which statistically will be effective in some patients, although the side effects of dual-immunity will relatively increase.